Hikma Pharmaceuticals (LON:HIK) Trading Down 14.1% – Here’s What Happened

Hikma Pharmaceuticals PLC (LON:HIK) shares traded down 14.1% during mid-day trading on Thursday . The stock traded as low as GBX 1,522 and last traded at GBX 1,522. 166,325,172 shares changed hands during trading, an increase of 7,989% from the average session volume of 2,056,107 shares. The stock had previously closed at GBX 1,771.

Analysts Set New Price Targets

A number of brokerages have weighed in on HIK. Deutsche Bank Aktiengesellschaft lowered their price target on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. JPMorgan Chase & Co. lowered their target price on Hikma Pharmaceuticals from GBX 2,600 to GBX 2,500 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Berenberg Bank lowered their target price on Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating on the stock in a research note on Thursday, October 16th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,600 target price on shares of Hikma Pharmaceuticals in a research note on Thursday, August 7th. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of GBX 2,615.

Hikma Pharmaceuticals Stock Performance

The stock has a fifty day simple moving average of GBX 1,740.80 and a two-hundred day simple moving average of GBX 1,898.69. The stock has a market cap of £3.37 billion, a price-to-earnings ratio of 9.11, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66.

Insider Buying and Selling at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Mazen Darwazah acquired 14,000 shares of the stock in a transaction dated Tuesday, September 16th. The stock was purchased at an average cost of GBX 1,603 per share, with a total value of £224,420. Also, insider Laura Balan Balan bought 3,500 shares of Hikma Pharmaceuticals stock in a transaction dated Friday, August 22nd. The stock was purchased at an average price of GBX 1,821 per share, with a total value of £63,735. 17.77% of the stock is owned by company insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.